Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksREDX.L Regulatory News (REDX)

  • There is currently no data for REDX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8 (OPD) - Jounce Therapeutics, Inc

9 Mar 2023 11:22

RNS Number : 4654S
Redx Pharma plc
09 March 2023
 

FORM 8 (OPD)

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Redx Pharma plc

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A

 

 

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Jounce Therapeutics, Inc ("Jounce")

(d) Is the discloser the offeror or the offeree?

Offeree

(e) Date position held:

The latest practicable date prior to the disclosure

9 March 2023

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

Yes - Redx Pharma plc

 

 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

Jounce common shares of $0.001 par value per share ("Shares")

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

0

-

0

-

(2) Cash-settled derivatives:

 

0

-

0

-

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

0

-

0

-

TOTAL:

0

-

0

-

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b) Rights to subscribe for new securities

 

Class of relevant security in relation to which subscription right exists:

N/A

Details, including nature of the rights concerned and relevant percentages:

N/A

 

 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

 

Registered holder

Class

Number of Shares

Percentage shareholding (%)

Sidley Austin Master Pension Trust ("SAMP Trust")

Jounce common shares of $0.001 par value per share

2,968

0.00569234%

SA Investment Partnership IV LLC ("SAIP IV")

Jounce common shares of $0.001 par value per share

1,978

0.00379361%

 

The SAMP Trust is a benefit plan trust that holds certain assets of Sidley Austin LLP's U.S.-based retirement plans. SAIP IV is an employees' securities company whose members are current or former partners or senior staff members of Sidley Austin LLP (or trusts formed by such persons).

 

Sidley Austin LLP is acting as legal adviser to RedCo II Master Fund, L.P. and RM Special Holdings 3, LLC.

 

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

No

Supplemental Form 8 (SBL)

No

 

 

Date of disclosure:

9 March 2023

Contact name:

Claire Solk, Group Company Secretary

Telephone number:

+44(0)1625 469900

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FEEFLFFLVIIAIIV
Date   Source Headline
1st Nov 20217:00 amRNSAppointment of Non-Executive Chair
11th Oct 20217:00 amRNSR&D Day and New Clinical Data for ROCK2 Inhibitor
5th Oct 20217:00 amRNSRedx to host Virtual R&D Day on 11 October 2021
27th Sep 20218:00 amRNSExercise of Options and Total Voting Rights
20th Sep 20214:59 pmRNSRedx Presents Encouraging Phase 1 Data for RXC004
17th Sep 202111:06 amRNSSecond Price Monitoring Extn
17th Sep 202111:00 amRNSPrice Monitoring Extension
16th Sep 202112:16 pmRNSPrice Monitoring Extension
16th Sep 202112:15 pmRNSSecond Price Monitoring Extn
16th Sep 202112:12 pmRNSSecond Price Monitoring Extn
16th Sep 202112:08 pmRNSPrice Monitoring Extension
14th Sep 20212:05 pmRNSSecond Price Monitoring Extn
14th Sep 20212:00 pmRNSPrice Monitoring Extension
14th Sep 202111:05 amRNSSecond Price Monitoring Extn
14th Sep 202111:00 amRNSPrice Monitoring Extension
13th Sep 20217:00 amRNSRXC004 Phase 1 data to be presented at ESMO 2021
2nd Sep 20217:00 amRNSMilestone Payment from Jazz Pharmaceuticals
27th Jul 20217:00 amRNSRedx Announces Phase 2 Dose Selection of RXC004
8th Jul 20211:43 pmRNSExercise of Options and Total Voting Rights
1st Jul 202111:08 amRNSNew Grant of Options and Director/PDMR Dealing
17th Jun 20217:00 amRNSRedx Receives Milestone Payment for RXC006
7th Jun 20217:00 amRNSInterim results for the six months ended 31 March
4th Jun 20217:00 amRNSChange of Auditor
3rd Jun 20217:00 amRNSFirst Subject Dosed in Phase 1 Study with RXC007
1st Jun 20217:00 amRNSDirectorate Change
24th May 20217:00 amRNSNotice of Interim Results
19th May 20217:00 amRNSAppointment of Non-Executive Director
5th May 20217:00 amRNSAppointment of Peter Collum as CFO
30th Apr 20219:00 amRNSConfirmation of post offer intention statements
28th Apr 20217:00 amRNSDosing of first patients with RXC004 and Anti-PD1
29th Mar 20219:00 amRNSRedx to present at AACR
15th Mar 20217:00 amRNSAppointment of Joint Broker
2nd Mar 202112:38 pmRNSResult of AGM and Directorate change
1st Mar 20219:57 amRNSNew Grant of Options
25th Feb 20217:00 amRNSPresentation at Cowen Healthcare Conference
5th Feb 20215:23 pmRNSNotice of AGM
27th Jan 20217:00 amRNSFinal Results for the Year Ended 30 September 2020
14th Jan 20217:00 amRNSNotice of Preliminary Results
29th Dec 20207:00 amRNSTR-1: Notification of major holdings
23rd Dec 20209:00 amRNSShare Purchases by Directors
22nd Dec 20205:13 pmRNSTR-1: Notification of major holdings
22nd Dec 20208:30 amRNSAdmission of Placing
21st Dec 202012:26 pmRNSResults of Open Offer and General Meeting
2nd Dec 20207:10 amRNSNew Grant of Options
2nd Dec 20207:00 amRNSPlacing and Open Offer Announcement
27th Oct 20207:00 amRNSAppointment of Chief Medical Officer
9th Sep 20207:00 amRNSResearch collaboration with Jazz Pharmaceuticals
3rd Sep 20203:00 pmRNSTR-1: Notification of major holdings
17th Aug 20202:05 pmRNSSecond Price Monitoring Extn
17th Aug 20202:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.